Therefore, targeting APOE-mediated inflammatory responses as part of therapeutic approaches for Alzheimer’s disease or neurodegeneration could prove useful and should be explored further as a potential solution. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.